Antireflux Mucosal Ablation vs Fundoplication for Refractory GERD
Key facts
- Who runs it
- Minia University
- Where
- Egypt1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 200 people enrolled
- Started
- 1 Jan 2023
- Ended
- 31 Dec 2024
- Type of study
- Observational, 2 groups
- Treatments tested
- Modified Antireflux Mucosal Ablation (ARMA)
- Laparoscopic Nissen Fundoplication
- Record updated
- 25 September 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 18 criteriaShow less
Who can take part
- Adult patients aged 18 years or older
- Diagnosis of refractory gastroesophageal reflux disease (GERD) confirmed by 24-hour pH monitoring and/or endoscopy
- Persistent GERD symptoms despite at least 8 weeks of optimized proton pump inhibitor (PPI) therapy
- Incomplete symptom control or patient intolerance to PPI therapy
- Eligible for either endoscopic or surgical antireflux intervention based on multidisciplinary team assessment
- Ability to provide informed consent for retrospective review of medical records
- Complete medical records available for the study period (January 2023 to December 2024)
Who cannot take part
- Prior antireflux surgery or endoscopic antireflux procedure
- Contraindication to general anesthesia or laparoscopic surgery
- Severe esophageal motility disorders (e.g., achalasia, diffuse esophageal spasm)
- Active malignancy or life expectancy less than 12 months
- Age less than 18 years
- Esophageal stricture or stenosis
- Hiatal hernia greater than 5 cm
- Barrett's esophagus with high-grade dysplasia or carcinoma
- Pregnancy or breastfeeding
- Incomplete follow-up data at 12 months
- Patients who declined participation in the retrospective record review
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This study compared two treatments for patients with gastroesophageal reflux disease (GERD) that did not improve with standard acid-reducing medications. The two treatments were Antireflux Mucosal Ablation (ARMA), a newer endoscopic procedure, and laparoscopic Nissen fundoplication, a well-established surgical procedure.
Read full original descriptionShow less
Two hundred patients with refractory GERD were enrolled between January 2023 and December 2024 at two tertiary referral centers in Egypt. One hundred patients underwent modified ARMA, and 100 patients underwent laparoscopic Nissen fundoplication. Treatment was determined by a multidisciplinary team according to a standardized protocol.
The study looked at quality of life scores related to GERD, whether patients were able to stop taking proton pump inhibitors (PPIs), and whether their DeMeester scores returned to normal at 12 months. It also examined surgical details, complications, recurrence rates, findings from routine endoscopy at 6 months, and overall treatment success.
This was a retrospective study, meaning the researchers reviewed existing medical records rather than assigning patients to treatments. The results may help doctors and patients choose the most appropriate treatment for refractory GERD.
The 2 groups in the trial
- Modified ARMA Group
One hundred patients with refractory GERD who underwent modified antireflux mucosal ablation (ARMA). Treatment allocation was protocol-driven and determined by a multidisciplinary team.
Treatment: Modified Antireflux Mucosal Ablation (ARMA)
- Laparoscopic Nissen Fundoplication Group
One hundred patients with refractory GERD who underwent laparoscopic Nissen fundoplication. Treatment allocation was protocol-driven and determined by a multidisciplinary team.
Treatment: Laparoscopic Nissen Fundoplication
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Antireflux Mucosal Ablation Versus Laparoscopic Nissen Fundoplication for Refractory Gastroesophageal Reflux Disease: A Comparative Cohort Study of 200 Patients
- Record updated
- 25 September 2026